Abstract: The present invention provides novel methods of inhibiting uterine fibroid disease and endometriosis in women comprising administering to a woman in need of treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is a benzyl group, or a pharmaceutically acceptable salt thereof.
Abstract: An aerosol-dispensable pharmaceutical composition consisting essentially of a combination of lidocaine free base, a pharmacologically-acceptable phenylephrine acid addition salt, and a pharmacologically-acceptable organic solvent, all dissolved in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane of the formula CF.sub.3 CH.sub.2 F (HFC-134a) and 1,1,1,2,3,3,3-heptafluoropropane of the formula CF.sub.3 CHFCF.sub.3 (HFC-227) or a combination of the said propellants, suitable for dispensing by means of a metered-dosage valve canister in which it is contained under pressure, avoids the necessity of premixing individual solutions by the physician just prior to use. The phenylephrine salt is preferably the hydrochloride and the solvent is preferably ethanol although other pharmacologically-acceptable solvents and pharmacologically-acceptable acid addition salts of phenylephrine may be employed.
Abstract: Unnatural dipeptoids of .alpha.-substituted Try-Phe derivatives are useful as agents in the treatment of panic disorders. These dipeptoids are CCK.sub.B antagonists having utility in the prevention of panic attacks in patients prone to these attacks.
Abstract: The present invention relates to new pharmaceutical compositions active in the therapy of sleep disorders comprising N-acetyl-5-methoxy-triptamine (melatonin) or one of its derivatives, preferably 2-iodo-N-acetyl-5-methoxy-triptamine (2-iodomelatonin), 2-bromo-N-acetyl-5-methoxy-triptamine (2-bromomelatonin), 2-chloro-N-acetyl-5-methoxy-triptamine (2-chloromelatonin) or 6-chloro-N-acetyl-5-methoxy-triptamine (6-chloromelatonin), at a dosage comprised between 10 and 100 mg, preferably comprised respectively between 20 and 80 mg between 10 and 20 mg and between 10 and 40 mg alone or in association with a benzodiazepinic derivative at a dosage comprised between 0.06 and 25 mg.
Type:
Grant
Filed:
December 2, 1993
Date of Patent:
July 4, 1995
Assignee:
Iflo-Istituto Farmacologico Lombardo S.A.S. di Giorgio e Ald. Laguzzi
Inventors:
Gabriele Biella, Franco Fraschini, Bojidar Stankov, Luigi F. Strambi
Abstract: A method is provided for inhibiting cholesterol biosynthesis by inhibiting de novo squalene production employing methylene phosphonoalkylphosphinate compounds.
Abstract: Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising lumisterol and/or tachysterol are also disclosed.
Type:
Grant
Filed:
September 23, 1993
Date of Patent:
June 6, 1995
Assignee:
Trustees of Boston University
Inventors:
Michael F. Holick, Zhiren Lu, Xiao Q. Tian
Abstract: A contraceptive method and regimen utilizing an initially greater amount of progestogen, which gradually tapers over the period in which the contraceptive is administered. The regimen includes a multiphasic combination and contraceptive kit containing at least 21 daily sequential dosage units divided into 3 phases. The first phase contains 6-8 dosage units, each containing a progestogen at a dosage equivalent in progestogenic activity to 75-150 .mu.g desogestrel and an estrogen at a dosage equivalent in estrogenic activity to 20-25 .mu.g ethinyl estradiol. The second phase contains 6-8 dosage units, each containing less progestogen than in the previous dosage units, but still having progestogen equivalent to 75-125 .mu.g desogestrel and an estrogen equivalent to 20 .mu.g ethinyl estradiol. The third phase contains 6-8 dosage units, each containing less progestogen than in the previous dosage units, but still containing a progestogen equivalent to 75-100 g desogestrel and an estrogen equivalent to 20 .mu.
Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8-positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.
Type:
Grant
Filed:
August 30, 1994
Date of Patent:
May 23, 1995
Assignee:
Allergan, Inc.
Inventors:
Charles Gluchowski, Michael E. Garst, James A. Burke, Larry A. Wheeler, Michael E. Garst
Abstract: Methods and pharmaceutical compositions for the treatment of dermatitis are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, which are administered to a patient suffering from dermatitis. The methods and compositions are particularly useful in the treatment of conditions characterized by hyperproliferation of keratinocytes, such as psoriasis.
Abstract: There is disclosed a composition for inhibiting uterine contractility by topical or local administration. The composition contains an omega fatty acid in combination with a cyclo-oxygenase inhibitor. Preferred omega fatty acids include docosahexaenoic acid and eicosapentaenoic acid, and preferred cyclo-oxygenase inhibitors include acetylsalicylic acid and salicylic acid. The composition may further include pharmaceutically acceptable carriers or diluents, and may be locally applied via intracervical or intrauterine application, or may be topically applied to the skin of the lower abdomen.
Abstract: The present invention is a pharmaceutical composition having a combination of an uricosuric agent such as probenecid or the like and an excitatory amino acid antagonist useful for treating a disease advantageously affected by treatment with an excitatory amino acid antagonist.
Type:
Grant
Filed:
April 19, 1993
Date of Patent:
April 18, 1995
Assignee:
Warner-Lambert Company
Inventors:
Christopher F. Bigge, Graham Johnson, Charles P. Taylor, Jr., Devin F. Welty
Abstract: Provided are methods of treating inflammation, arthritis and muscular dystrophy and preventing ischemia-induced cell damage employing certain phenol and benzamide compounds.
Abstract: A method of treating peri-menopasual syndrome comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
Abstract: This invention relates to methods of abrogating sperm motility utilizing the anti-bacterial, anti-viral agents butylurea, Nonoxynol-9 and benzalkonium chloride. This invention is further directed to anti-bacterial, anti-viral, non-irritating contraceptive compositions, and to methods of enhancing contraceptive capabilities of conventional contraceptive means as well as to enhanced conventional contraceptive means.
Type:
Grant
Filed:
June 3, 1993
Date of Patent:
February 7, 1995
Assignee:
Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
Abstract: Method for prophylaxis and treatment of heart diseases using a carbostyril derivative-of formula: ##STR1## wherein R.sup.1 is H or CN, and R.sup.2 and R.sup.3 are each H, alkyl optionally substituted by OH, cycloalkyl, alkenyl, phenyl, phenylalkyl having optionally substituents of alkoxyalkoxy, halogen, alkoxy, NO.sub.2, alkyl, CN, alkylthio or alkylsulfinyl on phenyl ring and having optionally OH-substituent on alkyl moiety, phenylsulfonylalkyl having optionally alkoxy substituent on phenyl ring, phenylthioalkyl, phenylsulfinylalkyl having optionally substituents of halogen or alkoxy on phenyl ring, phenoxyalkyl having optionally substituents of halogen or alkoxy on phenyl ring, pyridylalkyl having optionally substituents of halogen or alkoxy on pyridine ring, thienylalkyl, benzoylalkyl, anilinothiocarbonyl, benzoyl, pyridyl, phenylalkenyl, or group of --A--NR.sup.4 R.sup.5 (R.sup.4 and R.sup.
Abstract: Gamma-linolenic (GLA) and/or dihomo-gamma-linolenic acid (DGLA) may be used in the treatment of vulvar dystrophy and/or vaginal dryness. Other essential fatty acids of the n-6 or n-3 series may also be used in association with GLA and/or DGLA.
Abstract: The pharmaceutical, vaginal applicable preparation is characterized in that it contains, homogeneously sub-divided, at least one in water soluble poly-vinyl alcohol, at least one component A, selected from the group consisting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B for the local treatment of sexually transmissible or transmitted, respectively, diseases, and/or for vaginal infections, and occasionally one or more auxiliary agent(s), and in that it is in the form of a film having a thickness of the layer of from 0.05 to 0.5 mm, especially from 0.06 to 0.2 mm, preferably from 0.07 to 0.15 mm.
Abstract: A method for preventing oxidation by the cells lining the blood vessels of the body of a crystalline steroid alcohol comprises incorporating in the bloodstream a composition comprising all ascorbyl monoester of a saturated aliphatic monocarboxylic acid containing from 12 to 18 carbon atoms per molecule.
Abstract: The present invention is a method for sex determination in ratites, such as ostriches. The method includes the steps of administering a material that causes sex to be determined to a fertilized ratite egg and incubating the egg until it hatches. Preferably, the administering step includes the step of injecting the material into the egg and preferably before the injecting step, there is the step of drilling a hole into the eggshell of the egg. The material that determines sex in ratites includes natural estrogens or a functionally equivalent amount of its synthetic mimics to cause female development and natural nonaromatizable androgens or a functionally equivalent amount of its synthetic mimics to cause male development. Preferably, the material is estradiol-17beta (for female development) or dihydrotestosterone (for male development). A solution may, for example, be comprised of 1.2 milligrams of estradiol-17beta preferably dissolved in 40 microliters of 95% ethanol, or 7.